For supplement startups, FDA's 21 CFR Part 111 Current Good Manufacturing Practice (cGMP) regulations are frequently misunderstood. Many founders assume their contract manufacturer carries 100% of the regulatory responsibility. In reality, FDA treats own-label distributors as responsible under Part 111 for the quality oversight of products distributed under their brand name—including approving specifications, releasing finished batches for distribution, reviewing complaints, and investigating adverse events.
A structured set of Standard Operating Procedures (SOPs) defines how your brand qualifies contract manufacturers, establishes finished-product specifications (21 CFR § 111.70), reviews Certificates of Analysis (COAs) before batch release (21 CFR § 111.165), handles product complaints (21 CFR Subpart O), and manages Serious Adverse Event reporting under the Dietary Supplement and Nonprescription Drug Consumer Protection Act.
At Blue Ocean Regulatory, we build right-sized SOP frameworks specifically for brand owners that outsource manufacturing. Rather than copying bulky plant-floor procedures designed for a factory with 200 employees, we write practical procedures matched to your actual team structure—covering supplier qualification, specification control, batch release, complaint and adverse event handling, recall readiness, and Corrective and Preventive Actions (CAPA).
Beyond satisfying regulatory obligations, maintaining documented SOPs and batch release records strengthens commercial readiness when retail buyers, marketplace verification teams, or prospective investors conduct operational due diligence.
When selecting a regulatory consultant to build your quality system, look for a team that understands the specific division of responsibilities between an own-label brand owner and a contract manufacturer under 21 CFR Part 111—so your procedures are practical enough to follow on every production run.